Comprehensive characterization of the 293-ORF6 cell line

Developments in Biologicals

Volumn 123, Issue , 2006, Pages 225-233

  Butman, B T ^a   Lizonova, A ^a   Brough, D E ^a   Sowers, J M ^a   Sheets, R ^b   Gall, J ^a   Newton, P ^a   Gomez, P ^b  

^a GENVEC INC   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; VACCINE;

ADENOVIRUS; ANIMAL; CELL LINE; CONFERENCE PAPER; GENE DELETION; GENE VECTOR; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MOUSE; NUDE MOUSE; OPEN READING FRAME; PATHOGENICITY; STANDARD; VIRUS;

ADENOVIRIDAE; ANIMALS; CARCINOGENS; CELL LINE; GENETIC VECTORS; HUMANS; MICE; MICE, NUDE; OPEN READING FRAMES; SEQUENCE DELETION; VACCINES; VIRUSES;

EID: 33644611526     PISSN: 14246074     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (10)

1. Brough DE, Lizonova A, Hsu C, Kulesa V, Kovesdi I: A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. Journal of Virology 1996;70(9):6497.
2. Graham FL, Smiley J; Russell WC, Nairn R: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. Journal of General Virology 1977;36(1):59-74.
3. CBER's Points to consider in the characterization of cell lines used to produce. Biologicals, 1993, http://www.fda.gov/cber/gdlns/ptccell.pdf.
4. CBER's: Points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technology, 1985, http://www.fda.gov/ cber/gdlns/ptcdna.pdf.
5. CBER's: Guidance for human somatic cell therapy and gene therapy, 1998, http://www.fda.gov/cber/gdlns/somgene.pdf.
6. International Conference on Harmonisation (ICH) Q5A Document: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. Federal Register 1998;63(185):51074-51084.
7. International Conference on Harmonisation (ICH) Q5D Document: Quality of Biotechnological/Biological Products: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products. Federal Register 1998;63(182):50244-50249.
8. Palmer MS, van Leeven RH, Mahal SP, Campbell TA, Humphreys CB, Collinge J: Sequence Variation in Intron of Prion Protein Gene, Crucial for Complete Diagnostic Strategies. Human Mutation 1996;7(3):280-281.
9. Windl O, Dempster M, Estibeiro JP, Lathe R, de Silva R, Esmonde T, Will R, Springbett A, Campbell TA, Sidle KC, Palmer MS, Collinge J: Genetic basis of Creutzfeldt-Jakob disease in the United Kingdom: A systematic analysis of predisposing mutations and allelic variation in the PRNP gene. Human Genetics 1996;98(3):259-264.
10. Caughey B, Horiuchi M, Demaimay R, Raymond G: Assays of protease-resistant prion protein and its formation. Methods in Enzymology 1999;309:122-133.